Cargando…
2020–2021 Drug Updates in Hematologic Malignancies
During JADPRO Live Virtual 2021, Kirollos Hanna, PharmD, BCPS, BCOP, discussed the label indications of drugs and biologics in hematologic malignancies approved from late 2020 to late 2021, including mechanisms of action and various safety profiles so advanced practitioners can manage and treat pati...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126337/ https://www.ncbi.nlm.nih.gov/pubmed/35663174 http://dx.doi.org/10.6004/Jadpro.2022.13.3.20 |
_version_ | 1784712104784166912 |
---|---|
author | Hanna, Kirollos |
author_facet | Hanna, Kirollos |
author_sort | Hanna, Kirollos |
collection | PubMed |
description | During JADPRO Live Virtual 2021, Kirollos Hanna, PharmD, BCPS, BCOP, discussed the label indications of drugs and biologics in hematologic malignancies approved from late 2020 to late 2021, including mechanisms of action and various safety profiles so advanced practitioners can manage and treat patients safely with these new and approved therapeutic agents. In particular, CAR T-cell therapies were approved across many hematologic malignancies, along with PI3K inhibitors, anti-CD38 monoclonal antibodies, and immunotherapies. |
format | Online Article Text |
id | pubmed-9126337 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Harborside Press LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-91263372022-06-04 2020–2021 Drug Updates in Hematologic Malignancies Hanna, Kirollos J Adv Pract Oncol Meeting Reports During JADPRO Live Virtual 2021, Kirollos Hanna, PharmD, BCPS, BCOP, discussed the label indications of drugs and biologics in hematologic malignancies approved from late 2020 to late 2021, including mechanisms of action and various safety profiles so advanced practitioners can manage and treat patients safely with these new and approved therapeutic agents. In particular, CAR T-cell therapies were approved across many hematologic malignancies, along with PI3K inhibitors, anti-CD38 monoclonal antibodies, and immunotherapies. Harborside Press LLC 2022-04 2022-05-23 /pmc/articles/PMC9126337/ /pubmed/35663174 http://dx.doi.org/10.6004/Jadpro.2022.13.3.20 Text en © 2022 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Meeting Reports Hanna, Kirollos 2020–2021 Drug Updates in Hematologic Malignancies |
title | 2020–2021 Drug Updates in Hematologic Malignancies |
title_full | 2020–2021 Drug Updates in Hematologic Malignancies |
title_fullStr | 2020–2021 Drug Updates in Hematologic Malignancies |
title_full_unstemmed | 2020–2021 Drug Updates in Hematologic Malignancies |
title_short | 2020–2021 Drug Updates in Hematologic Malignancies |
title_sort | 2020–2021 drug updates in hematologic malignancies |
topic | Meeting Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126337/ https://www.ncbi.nlm.nih.gov/pubmed/35663174 http://dx.doi.org/10.6004/Jadpro.2022.13.3.20 |
work_keys_str_mv | AT hannakirollos 20202021drugupdatesinhematologicmalignancies |